Naftifine
Allylamine Antifungal — DERMATOLOGICALS
Also known as: naftifin, naftifine HCl, naftifine hydrochloride, naftifungin
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Naftifine is an ofp drug in the Allylamine Antifungal class catalogued in DrugCentral. It was first approved by the FDA in 1988. DrugCentral lists 7 molecular targets, including crtN, ERG2 and ERG1. Recorded indications include Tinea corporis, Tinea cruris and Tinea pedis.
- Approval status: ofp (first approved 1988 by the FDA).
- Drug class: Allylamine Antifungal.
- Molecular targets: crtN, ERG2, ERG1 and SIGMAR1 (7 listed in DrugCentral).
- Indications: Tinea corporis, Tinea cruris and Tinea pedis.
- ATC code: D01AE22 (Other antifungals for topical use).
- Molecular formula: C21H21N; molecular weight 287.41 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (3)
- Tinea corporis
- Tinea cruris
- Tinea pedis
Off-label uses (1)
- Pityriasis versicolor
Mechanism & targets
| Established pharmacologic class | Allylamine Antifungal |
|---|
Molecular targets (7)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Dehydrosqualene desaturase | crtN | unknown | IC50 6.53 |
| C-8 sterol isomerase | ERG2 | unknown | Ki 6.51 |
| Squalene monooxygenase | ERG1 | unknown | IC50 6.50 |
| Sigma non-opioid intracellular receptor 1 | SIGMAR1 | unknown | Ki 6.06 |
| 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase | EBP | unknown | Ki 5.82 |
| Squalene epoxidase | — | inhibitor | — |
| Squalene monooxygenase | SQLE | unknown | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1988-02-29 | FDA | — | MERZ PHARMS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
D01AE22 | DERMATOLOGICALS › ANTIFUNGALS FOR DERMATOLOGICAL USE › ANTIFUNGALS FOR TOPICAL USE › Other antifungals for topical use |
Chemical structure
| Molecular formula | C21H21N |
|---|---|
| Molecular weight | 287.41 g/mol |
| CAS number | 65472-88-0 |
| InChIKey | OZGNYLLQHRPOBR-DHZHZOJOSA-N |
| PubChem CID | 47641 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Naftifine used for?
DrugCentral lists the following indications for Naftifine: Tinea corporis, Tinea cruris and Tinea pedis.
How does Naftifine work?
Its molecular targets in DrugCentral include crtN, ERG2, ERG1 and SIGMAR1.
When was Naftifine first approved?
Naftifine was first approved by the FDA in 1988.
What drug class does Naftifine belong to?
Naftifine is in the Allylamine Antifungal class.
What is the chemical formula of Naftifine?
Naftifine has the molecular formula C21H21N and a molecular weight of 287.41 g/mol.
Browse: all drugs starting with N · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1872 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200493 — compound record and bioactivity
- PubChem CID 47641 — chemical identifiers
- DrugBank DB00735 — drug record
- FDA UNII 4FB1TON47A — substance identity
- DailyMed: FDA labels for Naftifine — current prescribing information (label search)
- UniProt Q99720 (SIGMAR1) — target protein
- UniProt Q15125 (EBP) — target protein
- UniProt Q14534 (SQLE) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.